Hologic (HOLX) sits in focus after recent share performance that includes a return of about 21% over the past year. This has prompted investors to reassess the women’s health specialist at around US$75 per share.
See our latest analysis for Hologic.
That 21.45% 1 year total shareholder return, compared with a relatively modest 1.52% year to date share price return, suggests earlier momentum has cooled somewhat. The stock is settling around US$75.69 as investors reassess potential risks and rewards.
If Hologic has you looking more broadly at healthcare opportunities, it could be worth seeing which other names stand out in our 36 healthcare AI stocks.
With shares now close to the average analyst price target and an intrinsic value estimate suggesting a near 30% discount, the key question is whether Hologic is quietly undervalued or whether the market is already pricing in future growth.
Most Popular Narrative: 1.3% Undervalued
Hologic's most followed narrative places fair value at about $76.67 per share, just above the recent $75.69 close. This frames the current move as a modest discount built on detailed growth and margin assumptions.
The global rise in preventive women's health and the aging population, combined with growing healthcare expenditure (especially in emerging markets), are positioning Hologic's core businesses for long-term growth. This underlies sustained demand for diagnostic and screening products and should drive higher utilization and recurring revenue.
Curious what turns that broad theme into a concrete fair value close to $77? The narrative leans on measured revenue growth, rising margins, and a future earnings multiple that has been carefully stepped down from today’s level. All of this is tied together by an 8% discount rate and earnings projections that stretch out beyond this decade.
Result: Fair Value of $76.67 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still need to weigh issues like ongoing tariff costs and pressure in China and Africa, which could challenge the margin and earnings story.
Find out about the key risks to this Hologic narrative.
Next Steps
Seeing both risks and rewards in the story so far? It is worth checking the data for yourself and deciding how it all stacks up next to the 2 key rewards and 1 important warning sign
Looking for more investment ideas?
If you stop with just one stock, you could miss out on other opportunities that better match your goals, risk comfort, and income needs.
- Target potential mispricings by scanning for quality businesses trading at appealing levels through the 61 high quality undervalued stocks.
- Strengthen your focus on capital preservation by checking companies in the 69 resilient stocks with low risk scores that score well on resilience.
- Hunt for underfollowed names with strong fundamentals using the screener containing 25 high quality undiscovered gems before the crowd pays attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com